TürkiyeSGK and reimbursement
SGK adds a drug that prevents hereditary angioedema attacks to reimbursement
Based on a single news source or an institutional announcement. The level of scientific evidence is low; check the details with a doctor.
On April 8, 2026, a drug that prevents attacks in hereditary angioedema was added to SGK (Social Security Institution) reimbursement coverage. The regulation was published in the Resmî Gazete (Official Gazette) on the same day. The news report did not name the drug. One drug each for achondroplasia and cystinuria will also be brought in from abroad. Support for special formula foods in celiac disease and some metabolic diseases increased by 30%.
What does it mean for patients and families?
People with HAE can ask their own physician about the new coverage.
Source
TGRT Haber: SGK’dan ilaç ve nakdi destek duyurusu! Resmi Gazete'de yayımlandı
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Hereditary angioedema (HAE)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.